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DISCUSSION
Dr Fred Weaver (Los Angeles, Calif). I would like to con-
gratulate Dr Nehler on a fine presentation and all the Circulase
investigators on a well designed and conducted clinical trial. The
objective of this trial was to examine the utility of lipo-ecraprost, a
prostaglandin analog, as an adjunct to lower extremity revascular-
ization in patients with chronic limb-threatening ischemia. Intra-
venous infusion of lipo-ecraprost or placebo control was com-
menced at 72 hours after revascularization and continued for 5
days per week for 8 weeks. The therapeutic groups were well
matched for degree of ischemia, type of revascularization required,
and comorbid conditions. Subsequent primary and assisted pri-
mary patency of revascularization procedures performed were sim-
ilar between placebo and the study drug groups.
Despite the fact that this trial did not show any advantage of
lipo-ecraprost over placebo in the primary end point of 6-month
amputation-free survival, there are a number of valuable findings in
this study that require comment. First, the complexity of designing
and conducting a trial in patients with chronic limb ischemia is
significant. Providing a stratification of risk and randomization that
provides for an apple-to-apple comparison requires significant
forethought and valid statistical methodology. In large part, the
trial accomplished this objective and is a model for future studies
on patients with chronic limb ischemia.
Second, the results of lower extremity revascularization docu-
mented in this trial for patients with limb-threatening ischemia are
sobering. At 6 months, either amputation or mortality had oc-
curred in 26% and 21% in the placebo and the study drug groups,
respectively. In addition to those clinical failures was a finding that
only a third of patients in both arms were rest-pain or ulcer-free at
6 months. Consequently, the majority of patients in both arms
were clinical failures at 6 months despite the presence of a success-
ful revascularization in over 80%.
Third, lipo-ecraprost was poorly tolerated, with less than 50%
of patients actually receiving the total number of infusions directed
by the protocol. The adverse event rate in the lipo-ecraprost arm
was very significant, with 2650 adverse events compared with only
947 in the placebo arm. Although I have not performed a statistical
analysis, it appears that this increase in the adverse event rate with
lipo-ecraprost is one important statistically significant finding of
this study.
I have a number of questions for Dr Nehler. Three hundred
thirteen patients were randomized but only 284 received the
randomized treatment. Why? What happened to the 29 patients
who were randomized but not treated? Your analysis was based on
an intent-to-treat strategy. My understanding is that once a patient
is randomized in intent-to-treat analyses, they are included in the
statistical analysis even if they did not receive the randomized
treatment. This was not the case in your analysis where these 29
randomized patients were excluded. Could you explain the statis-
tical rationale for the exclusion of these 29 patients?
Two, the initial power estimates for this study were predicated
on a combined amputation mortality rate of 30%, which becomes
significant given the negative findings of the study. In your paper,
you comment on this power calculation and then cite two other
prospective studies with a combined amputation mortality rate of
less than 25%. This raises the issue as to whether the current study
is underpowered. The statistical concern is further accentuated by
the fact that less than 50% of patients received all infusions of the
study drug. Consequently, are you and your fellow investigators
satisfied that the results reported today are valid and exclude a
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potential adjunctive benefit even though it appears that you may
have underpowered the study?
Three, revascularization was performed using both open and
endovascular procedures. In your patency analysis, did you sepa-
rate the patency outcomes of open and endovascular procedures? If
so, what were the findings, and were there any significant differ-
ences between open and endovascular primary and primary assisted
patencies at 6 months?
Four, why was the lipo-ecraprost dose of 60 g used in this
study? As you mentioned in your discussion, salutary results have
been reported for a dose of 10 g in the chronic limb ischemia
patient. It would seem that if 10 g with uncorrected occlusive
disease is beneficial, then six times that dose in patients in whom
the occlusive disease has been surgically treated is overkill and
could lead to intolerance of the study drug, which was found in this
study. What was the reason for the 60-g dose chosen in this
study?
In conclusion, I congratulate Dr Nehler and his colleagues on
a well designed, albeit negative study, and I look forward to his
comments to the above questions. Thank you for your attention.
Dr Mark Nehler. Thanks, Dr Weaver, for those excellent
comments and questions. The first question was the intent-to-treat
group a protocol design where we wanted to include the patients
who had received at least one dose of the study material. In the
top-line analysis tables of the FCSR, we did look at all of the
patients and adding the excluded patients did not change the
conclusions. Patients who did not receive study material despite
randomization was due to change in clinical status following index
revascularization that precluded dosing within the required 72-
hour window.
With regards to the powering of the study, that is one of the
major criticisms. At the time that we did the design for this trial,
BASIL had not finished, PREVENT-III was not done, so there was
a relative dearth of level 1 data in critical limb ischemia patients. We
were using older historic controls to try to calculate what we
thought was going to be the 6-month event rates, some of them
which were actually earlier prostaglandin trials from Europe with
smaller numbers of patients. We did miscalculate.
Although I put the more recent trials in the discussion and in
the introduction, the event rates do not add up completely to our
calculations. We could have underpowered the study. One of the
worst things you can do in designing a clinical trial is to predict an
event rate that you do not achieve because obviously patients
without events cannot be modified by your agent, so it is much
better to predict an event rate that is lower than what you think you
are going to get and then get more events because you have amuch
better chance of having a positive trial. That is a valid criticism of
our design.
Open vs endovascular-assisted patency rates were not com-
pared primarily because we had only a small number of endovas-
cular patients and adherence to the assisted protocol was poor,
with many patients censured from the life-table. We compared
amputations between the two groups and there was no difference.
The rationale for the study dose was brought up in the steering
committee when we discussed the results of this trial. At the time of
trial design, the agent efficacy was felt to be dose-related, and
unpublished results that showed some benefit at the highest toler-
able dose. The sponsor felt the reason that previous trials had been
mixed was because of inadequate dosage. In retrospect, the dosage
probably was too high, especially to be tolerated in this population.
Interestingly, the number of dropouts in the stand-alone trial just
published in JVS a few months ago is much less than the current
adjunctive trial. Patients with unreconstructable critical limb isch-
emia are willing to tolerate side effects and finish their course of
therapy, but revascularized patients are much less tolerant.
Of note, Mitsubishi Pharma has actually sold this agent to a
smaller company in Japan that is going to continue to market it.
This particular product is used a tremendous amount in China.
That is probably their number one worldwide usage right now.
The whole issue of prostaglandins has not really gone away
because there is a recent study out of theAnnals of Surgery from an
Italian group where they did a multicenter trial in acute limb
ischemia using iloprost both intra-arterially at the time of either
revascularization or thrombolysis as well as an adjunctive intrave-
nous infusion for a week postprocedurally, with a positive result.
They dropped their amputation mortality at 3 months from 20% in
the placebo group to 15% in the treatment group, so in Europe and
in other parts of the world prostaglandins still get used a tremen-
dous amount.
Dr Ted Kohler (Seattle, Wash). Very nice study, Mark. I
compliment your group for publishing negative results, which are
just as important as positive ones. I would not worry too much
about being underpowered. Underpowering is a problem for
potential type II errors, but this is usually when there is an observed
difference but the P value does not reach statistical significance due
to a lack of adequate sample size. In your case, there is no observed
difference between the two groups, so there is very little concern
that there may be a small difference, and if there were a difference,
it would not likely clinically significant.
Dr Nehler. That is an excellent point. Actually of the two
trials, probably the only thing that we were worried about being
underpowered for was the potential for adverse cardiac events in
the stand-alone trial where we did see a trend, but it was not
significant. I think much more crucial in this trial was the dosage.
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